Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until September, 2020.

  1. Novel sanitizer/disinfectants against viral infections with long-lasting effect

    SBC: CAMELLIX, LLC            Topic: NIAID

    AbstractNorovirus is the most common cause of acute gastroenteritis in the United Statesassociated annually withmillion illnesseshospitalizations anddeathsUS CDCOverview about NorovirusNorovirus is one of the nonenveloped viruses that are resistant to alcohol sanitizationAccording to US CDC Guidelines for the Prevention and Control of Norovirus Gastroenteritis Outbreaks in Healthcare Settingsthe p ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Developing a Small Peptide to Control Autoimmune Inflammation In Type 1 Diabetes

    SBC: Op-T-Mune, Inc            Topic: NIAID

    TypeDiabetesT Daffects an ever growing populationWhile this disease typically has been associated with juvenilesthe disease in adult populations is rapidly increasingThe defining clinical component is insulin losswhich occurs because of sustained inflammation in the isletsAt present there is no means to prevent or reverse insulin lossA major inflammatory pathway in T D that contributes to insulin ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Preventing Vascular Complications in Type 1 Diabetes: Muscle Metabolic Monitoring

    SBC: Infrared Rx, Inc.            Topic: NIDDK

    Preventing Vascular Complications in TypeDiabetesMuscle Metabolic Monitoring Abstract Measurements of muscle metabolism and blood flow using near infrared spectroscopyNIRShave progressively increasedas has the number of companies selling NIRS based devicesThis technology represents the present and future modality for non invasively characterizing normal and abnormal muscle physiology in health as ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. In Vivo Studies of a Novel HDAC Inhibitor for Treating Hemoglobin Disorders

    SBC: Cetya Therapeutics, Inc.            Topic: NHLBI

    PROJECT SUMMARY Thehemoglobinopathies are prevalent genetic blood diseases with few treatment optionsIt is estimate thatof the worldandapos s population carries an abnormal hemoglobin gene withinfants born annually with a severe life threatening hemoglobinopathyDrug mediated induction of normalbut developmentally silencedfetal hemoglobinHbFexpression reduces anemia and ameliorates clinical severit ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government